<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; advantage</title>
	<atom:link href="http://www.tapanray.in/tag/advantage/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>In the Age of AI, Why Emotional Intelligence Is the New Competitive Edge in Indian Pharma Marketing</title>
		<link>http://www.tapanray.in/in-the-age-of-ai-why-emotional-intelligence-is-the-new-competitive-edge-in-indian-pharma-marketing/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=in-the-age-of-ai-why-emotional-intelligence-is-the-new-competitive-edge-in-indian-pharma-marketing</link>
		<comments>http://www.tapanray.in/in-the-age-of-ai-why-emotional-intelligence-is-the-new-competitive-edge-in-indian-pharma-marketing/#comments</comments>
		<pubDate>Sun, 16 Nov 2025 06:32:16 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[advantage]]></category>
		<category><![CDATA[AI]]></category>
		<category><![CDATA[Artificial]]></category>
		<category><![CDATA[competitive]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[edge]]></category>
		<category><![CDATA[emotional]]></category>
		<category><![CDATA[empathy]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[Intelligence]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=11000</guid>
		<description><![CDATA[In today’s AI-driven world — where scientific excellence, product claims, and competitive pricing are no longer enough to differentiate pharmaceutical companies — Emotional Intelligence (EI) is rapidly emerging as the new strategic advantage in Indian pharma marketing. As doctors face shrinking time, patients demand &#8230; <a href="http://www.tapanray.in/in-the-age-of-ai-why-emotional-intelligence-is-the-new-competitive-edge-in-indian-pharma-marketing/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/in-the-age-of-ai-why-emotional-intelligence-is-the-new-competitive-edge-in-indian-pharma-marketing/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>More Glivec Like Deals in China and Mounting Global Challenges: Innovators poised Joining Biosimilar Bandwagon</title>
		<link>http://www.tapanray.in/more-glivec-like-deals-in-china-and-mounting-global-challenges-innovators-poised-joining-biosimilar-bandwagon/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=more-glivec-like-deals-in-china-and-mounting-global-challenges-innovators-poised-joining-biosimilar-bandwagon</link>
		<comments>http://www.tapanray.in/more-glivec-like-deals-in-china-and-mounting-global-challenges-innovators-poised-joining-biosimilar-bandwagon/#comments</comments>
		<pubDate>Mon, 15 Apr 2013 00:00:04 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[12years]]></category>
		<category><![CDATA[AbVie]]></category>
		<category><![CDATA[advantage]]></category>
		<category><![CDATA[Amgen]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[bandwagon]]></category>
		<category><![CDATA[Barriers]]></category>
		<category><![CDATA[biologics]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[drivers]]></category>
		<category><![CDATA[DRL]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[EliLilly]]></category>
		<category><![CDATA[entry]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[Genentech]]></category>
		<category><![CDATA[Glivec]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Herceptin]]></category>
		<category><![CDATA[Hospira]]></category>
		<category><![CDATA[Humira]]></category>
		<category><![CDATA[IMS]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Innovators]]></category>
		<category><![CDATA[J&J]]></category>
		<category><![CDATA[joining]]></category>
		<category><![CDATA[LG]]></category>
		<category><![CDATA[low]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[products]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Remicade]]></category>
		<category><![CDATA[Rituxan]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Teva]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[win-win]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2164</guid>
		<description><![CDATA[Pressure from the emerging markets on pricing of patented products is mounting fast. This time the country involved is China. Recently, the Health Minister of China who stepped down last month after a seven-year stint in the top health job &#8230; <a href="http://www.tapanray.in/more-glivec-like-deals-in-china-and-mounting-global-challenges-innovators-poised-joining-biosimilar-bandwagon/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/more-glivec-like-deals-in-china-and-mounting-global-challenges-innovators-poised-joining-biosimilar-bandwagon/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
